EIF2AK3 and myeloid sarcoma: Since PERK activation in oligodendrocytes has been reported in many demyelinating diseases (e.g., MS) of the CNS, it poses a challenge for researchers to distinguish between myelin thinning caused by PERK activation and thinner myelin generated by remyelination following demyelination.